We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

Back to rankings

212 hedge funds and large institutions have $2.12B invested in Portola Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 46 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 46

48% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 25

10% more capital invested

Capital invested by funds: $1.92B → $2.12B (+$201M)

5% more funds holding

Funds holding: 201 → 212 (+11)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

51% less call options, than puts

Call options by funds: $9.14M | Put options by funds: $18.6M

Holders
212
Holders Change
+11
Holders Change %
+5.47%
% of All Funds
4.65%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
37
Increased
92
Reduced
46
Closed
25
Calls
$9.14M
Puts
$18.6M
Net Calls
-$9.46M
Net Calls Change
-$2.74M

Top Buyers

Rank Fund Capital Flow
1
William Blair Investment Management
William Blair Investment Management
Illinois
+$52.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$34.1M
3
BlackRock
BlackRock
New York
+$25.1M
4
FLAM
First Light Asset Management
Minnesota
+$21.4M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$20.5M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$17.4M
2
CCM
Cadian Capital Management
New York
-$11.9M
3
State Street
State Street
Massachusetts
-$11.8M
4
ACM
Asymmetry Capital Management
California
-$10.5M
5
Morgan Stanley
Morgan Stanley
New York
-$7.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
51
Balyasny Asset Management
Illinois
$5.68M +$2.2M +78,508 +59%
Morgan Stanley
52
Morgan Stanley
New York
$5.29M -$7.67M -273,246 -58%
CS
53
Candriam SCA
Luxembourg
$5.21M – – –
UBS Group
54
UBS Group
Switzerland
$5.06M -$111K -3,942 -2%
Creative Planning
55
Creative Planning
Kansas
$4.99M -$457K -16,297 -8%
GKIM
56
GW&K Investment Management
Massachusetts
$4.77M +$1.47M +52,248 +42%
Rafferty Asset Management
57
Rafferty Asset Management
New York
$4.52M -$662K -23,569 -12%
State of Wisconsin Investment Board
58
State of Wisconsin Investment Board
Wisconsin
$4.37M +$902K +32,119 +25%
CEP
59
Chicago Equity Partners
Illinois
$4.28M +$4.48M +159,504 New
William Blair & Company
60
William Blair & Company
Illinois
$4.09M +$143K +5,105 +3%
HCM
61
Harvey Capital Management
Florida
$4.09M -$50.5K -1,800 -1%
ACM
62
Asymmetry Capital Management
California
$4.03M -$10.5M -375,431 -71%
American Century Companies
63
American Century Companies
Missouri
$3.71M +$232K +8,279 +6%
Swiss National Bank
64
Swiss National Bank
Switzerland
$3.64M +$688K +24,500 +22%
CS
65
Credit Suisse
Switzerland
$3.63M +$2.06M +73,515 +119%
GH
66
GAM Holding
Switzerland
$3.62M – – –
SSA
67
Schonfeld Strategic Advisors
New York
$3.4M +$712K +25,365 +25%
PAMU
68
Pictet Asset Management (UK)
United Kingdom
$3.4M +$3.56M +126,800 New
California Public Employees Retirement System
69
California Public Employees Retirement System
California
$3.4M +$1.45M +51,772 +69%
SGA
70
Sector Gamma AS
Norway
$3.38M -$2.19M -78,000 -38%
Citigroup
71
Citigroup
New York
$3.35M -$2.79M -99,343 -44%
Millennium Management
72
Millennium Management
New York
$3.24M +$3.06M +108,849 +912%
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
$3.12M +$385K +13,702 +13%
TCM
74
Tekla Capital Management
Massachusetts
$3.1M – – –
Barclays
75
Barclays
United Kingdom
$3.06M +$1.59M +56,603 +98%
1 2
3
4 5

PTLA Hedge Fund Activity: Q3 2019 in Review

212 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2019, worth a combined $2.12B — up 10% from $1.92B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PTLA positions and 25 closed out — a net gain of 12 holders — while 92 added to existing stakes and 46 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $52.3M. The largest seller was JP Morgan Chase, cutting an estimated $17.4M.

  • 212 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2019, up from 201 in Q2 2019.
  • Funds reported $2.12B of Portola Pharmaceuticals, Inc. stock for Q3 2019, up 10% quarter-over-quarter.
  • 37 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2019 and 25 closed out, a net change of +12 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2019 was William Blair Investment Management, an estimated $52.3M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2019 was JP Morgan Chase, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2019.